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Protein modification with ISG15 blocks coxsackievirus 
pathology by antiviral and metabolic reprogramming
Meike Kespohl1,2, Clara Bredow1, Karin Klingel3, Martin Voß1, Anna Paeschke1, Martin Zickler1*, 
Wolfgang Poller4, Ziya Kaya5,6, Johannes Eckstein1, Henry Fechner7, Joachim Spranger8, 
Michael Fähling9, Eva Katrin Wirth8, Lilliana Radoshevich10, Fabien Thery11,12, 
Francis Impens11,12,13, Nikolaus Berndt1,14, Klaus-Peter Knobeloch15, Antje Beling1,2†
Protein modification with ISG15 (ISGylation) represents a major type I IFN–induced antimicrobial system. Common 
mechanisms of action and species-specific aspects of ISGylation, however, are still ill defined and controversial. 
We used a multiphasic coxsackievirus B3 (CV) infection model with a first wave resulting in hepatic injury of the 
liver, followed by a second wave culminating in cardiac damage. This study shows that ISGylation sets nonhemato-
poietic cells into a resistant state, being indispensable for CV control, which is accomplished by synergistic activity 
of ISG15 on antiviral IFIT1/3 proteins. Concurrent with altered energy demands, ISG15 also adapts liver metabolism 
during infection. Shotgun proteomics, in combination with metabolic network modeling, revealed that ISG15 in-
creases the oxidative capacity and promotes gluconeogenesis in liver cells. Cells lacking the activity of the ISG15- 
specific protease USP18 exhibit increased resistance to clinically relevant CV strains, therefore suggesting that 
stabilizing ISGylation by inhibiting USP18 could be exploited for CV-associated human pathologies.
INTRODUCTION
Early in an encounter between the pathogen and a cell, receptors 
located on the cell surface, in the cytosol, or in endosomal compart-
ments engage with nucleic acid or non–nucleic acid pathogen- 
associated molecular patterns (PAMPs) to mount host responses to 
combat infection. Specific gene expression patterns and posttran-
scriptional control mechanisms combat pathogens on multiple levels 
and stages during disease development. As a first line of defense, cells 
produce type I interferons (IFNs), which orchestrate a complex 
defense network in both infected and noninfected cells (1). The 
ubiquitin family protein IFN-stimulated gene of 15 kDa (ISG15) and 
its conjugation machinery, comprising the E1-activating enzyme 
Ube1L, the E2-conjugating enzyme Ube2L6, and the Herc5 E3 ligase 
(Herc6 in mice), represent a bona fide example of such an IFN- 
induced, broad-spectrum antimicrobial system (1–4). Infection studies 
using ISG15- and Ube1L-knockout (ko) mouse models revealed 
that modification of target proteins with ISG15, a process known as 
ISGylation, is critical in the defense against pathogens including in-
fluenza B, Sindbis viruses, and Listeria monocytogenes (3, 5, 6). The 
antimicrobial function of ISG15 reported in mice is also present 
in human ISG15 with proven antiviral activity, for example, against 
influenza A and B virus, HIV, and human papilloma virus (1). 
ISGylation is a reversible process, and de-ISGylation is catalyzed by 
the ISG15-specific protease USP18 (7). In addition to its ISG15- 
specific protease activity, USP18 acts as a potent negative regulator 
of IFN signaling (8). Concordantly, complete deletion of USP18 causes 
an increase in the IFN response, whereas selective inactivation of its 
protease activity in USP18C61A/C61A (USP18C61A) mice increases 
the pool of ISGylated proteins without affecting the IFN signaling 
pathway (9). Notably, enhanced ISGylation in USP18C61A mice 
increases the antiviral activity against influenza B and vaccinia virus, 
even in comparison to wild-type controls (9). It has been reported 
that unconjugated ISG15 in human cells, but not in mouse cells, 
inhibits proteasomal degradation of USP18, thereby preventing un-
controlled activation of the IFN response (10, 11). Likewise, cells 
derived from ISG15-deficient patients exhibited reduced levels of 
USP18, accompanied by increased IFN signaling (10, 11). However, 
these species-specific differences between ISG15 and USP18 func-
tion remain poorly defined.
Furthermore, the underlying mechanisms how ISGylation oper-
ates within the context of a whole organism to protect it from infec-
tion are largely unknown. Cell culture–based studies from various 
laboratories provided insights into how ISG15 reduces the pathogenic 
burden during infection. One mode of action for ISG15-mediated 
reduction of the viral load involves a direct interference of ISG15 
with viral proteins that are required for replication (12, 13). In other 
cases, ISG15 stimulates antiviral effector pathways of the host (14) 
or it controls exosome formation, which prevents pathogen spread 
(15). Moreover, ISG15 modifies endoplasmic reticulum and Golgi 
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proteins to affect the secretion of cytokines (3, 16) and regulates the 
polarization and function of macrophages (17, 18). Thereby, ISGylation 
influences multiple important cellular processes needed for pathogen 
control. Nevertheless, ISG15 is not critical to counteract all kinds of 
pathogens (1), and it was clearly shown that free ISG15 can exert 
antimicrobial activity without forming covalent linkages to target 
substrates (2). Free, intracellular ISG15 can either interact with 
cellular proteins (19) or, as a secreted protein, bind to lymphocyte 
function–associated antigen–1 (LFA-1) receptor to stimulate IFN- 
secretion by natural killer (NK) cells (4, 20).
Our previous work documented that ISG15 prevents the mani-
festation of inflammatory cardiomyopathy (21), a chronic debilitating 
sequela of experimental coxsackievirus B3 (CV)–induced myocar-
ditis in mice (22). CV disease has substantial medical and socioeco-
nomic impact. During periods of high CV prevalence, particularly 
newborn infants and young children are at risk of life-threatening 
hepatitis, myocarditis, encephalomyelitis, and coagulopathy, result-
ing in multisystem sepsis (23). CV disease can be mimicked in mice, 
where, similarly to humans, CV triggers a multiphasic systemic dis-
ease that affects various organs at different stages with the possibility 
of viral genome persistence and chronic tissue injury (24). Early 
upon CV infection, mice show a robust systemic IFN response (25). 
At this stage, IFN signaling limits viral cytotoxicity and tissue de-
struction, particularly in the liver, and enhances the chances of survival 
(26, 27). Although not precisely characterized during CV infection 
of mice, antiviral responses of the host against CV infection are sup-
ported by an IFN-induced remodeling of cellular metabolism (28), 
with the liver having a central integrating role of systemic IFN input 
in the context of systemic inflammatory responses (29). The bio-
synthesis of molecules, needed for an efficient antiviral response 
against CV, consumes large proportions of cellular adenosine tri-
phosphate (ATP), and in infected cells, IFNs induce processes that 
activate the uptake and turnover of glucose (28). After the first viremia, 
when systemic IFN production gradually declines, a second viremia 
and replication phase of CV emerges in heart tissue, culminating in 
inflammatory tissue damage and cardiac dysfunction (30). In this 
state, IFN signaling constrains CV pathology as well (31, 32). Despite 
the clear physiological relevance of IFN responses, molecular aspects 
of how ISG15 operates during CV infection remain elusive. Here, 
we report that protein ISGylation is required in nonhematopoietic 
cells to set these cells into an antiviral state. ISG15-mediated protec-
tion from viral cytotoxicity is accomplished by reprogramming the 
central liver metabolism, ensuring glucose homeostasis during 
infection, and an cumulative activity of ISG15 with the expression 
levels of other required antiviral effectors such as IFIT1/3 proteins. 
On the basis of these mechanistic aspects, we demonstrate the 
physiological relevance and therapeutic strategies of ISGylation for 
CV-associated human pathologies.
RESULTS
Multiphasic inhibition of the CV burden by ISGylation
The ISG15 system is activated by IFNs during the multistage course 
of CV infection (21, 27). The formation of ISG15 conjugates com-
menced in liver, pancreas, spleen, and heart tissue 1.5 days (36 hours) 
after CV infection, and protein ISGylation increased further upon 
progression of the disease (Fig. 1, A and B, and fig. S1A). In com-
parison to heart tissue, the protein expression level of free ISG15 
dropped in liver tissue on day 6 (Fig. 1, A and B, and fig. S1A). In 
line with this, we detected differences in both liver and heart tissue 
concerning the load with infectious viral particles. While we found 
no infectious virus in the liver on day 6, in heart tissue, virus titers 
were elevated by this stage (Fig. 1, C and D). To distinguish between 
ISGylation-dependent functions and those mediated by free ISG15, 
we investigated the viral burden during CV infection in ISG15−/− and 
Ube1L−/− mice. Deletion of the ISG15-specific E1 enzyme Ube1L 
prevents ISGylation, with no relevant effect on the function of free 
ISG15 (fig. S1B) (33). When we compared wild-type, Ube1L−/−, and 
ISG15−/− mice, we detected similar viral titers in all organs 1.5 days 
after CV infection. In contrast, viral titers in the liver, pancreas, and 
spleen of both ISG15−/− and Ube1L−/− mice were significantly in-
creased in comparison to wild-type controls after 3 days. ISGylation 
accelerated CV clearance from liver and spleen, as reflected by higher 
CV titers in ISG15−/− and Ube1L−/− mice compared to wild type after 
6 days (Fig. 1C and fig. S1, C and D). Beyond day 3 after infection, 
we observed no contribution of ISGylation to viral clearance in the 
pancreas but found increased viral titer in ISG15−/− mice in compar-
ison to wild-type controls and Ube1L−/− mice (fig. S1C). In heart 
tissue, viral titers increased after 1.5 days and remained at high levels 
up to day 8. Viral load in the heart from ISG15−/− and Ube1L−/− mice 
was increased 6 and 8 days after infection, illustrating that ISGylation 
also suppressed the second CV replication peak, which occurs in 
heart tissue (Fig. 1D). Together, protein ISGylation blocked virus 
replication in the liver, spleen, and pancreas most potently after 
3 days of infection and in heart tissue after 6 days of infection.
Inactivation of ISG15-specific protease USP18 increases 
resistance to CV infection
To evaluate the physiological relevance and potential therapeutic 
strategies of ISGylation in the context of CV infection, we analyzed 
mice selectively lacking the activity of the ISG15-specific protease 
USP18 (USP18C61A/C61A). CV infection of these USP18C61A mice 
was characterized by enriched pools of ISGylated proteins, as previ-
ously reported (9), and is shown exemplarily for heart tissue (Fig. 1E) 
and liver (fig. S2A). The first phase of CV replication in USP18C61A 
was similar to wild-type controls (fig. S2B). In clear contrast, the 
second phase of viral replication was inhibited once de-ISGylation 
was blocked, as reflected by suppressed viral titers after 6 days of 
infection in heart tissue of USP18C61A mice (Fig. 1F). This finding 
prompted us to investigate the antiviral effect by USP18 protease 
inactivation in cell culture experiments. Therefore, USP18C61A mice 
were crossed with ISG15−/− mice, and primary cardiomyocytes were 
isolated from USP18C61A ISG15−/− embryos. ISGylation was in-
duced in both USP18C61A ISG15−/− and ISG15−/− cells reconstituted 
with ISG15 by adenoviral transduction. This cell culture model nicely 
reflected the increased abundance of ISGylated proteins (Fig. 1G) 
that we observed in the heart of USP18C61A mice (Fig. 1E). Upon 
infection, hyper-ISGylation, caused by the lack of USP18 protease 
activity, substantially reduced viral replication. Lower viral genome 
copy numbers, reduced VP1 expression, and suppressed viral titers 
were detected in USP18C61A cardiomyocytes, in comparison to USP18 
wild-type cardiomyocytes (Fig. 1, H to J). These results support our 
in vivo data obtained from USP18C61A mice.
Protection from CV pathology requires ISGylation 
in nonhematopoietic cells
Because chemotactic cytokines like CXCL-10 (34), proinflammatory 
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Fig. 1. ISGylation suppresses CV titers at different phases of infection. Wild-type (wt), ISG15−/−, and Ube1L−/− mice were infected with 1 × 105 pfu of CV Nancy and sacrificed 
at the indicated points in time post infection (p.i.). Tissue from (A) liver and (B) heart of wild-type mice was subjected to Western blot analysis using an ISG15-specific antibody. 
Each lane represents tissue homogenates obtained from a different animal. (C and D) Infectious viral particles were quantified in the respective organs obtained from 
wild-type, ISG15−/−, and Ube1L−/− mice by plaque assay during CV infection. Each dot represents a different animal; data are summarized as median values. Student’s 
t tests were conducted. P values of <0.05 are indicated in the graph. (E to J) USP18C61A and wild-type littermate controls were infected with 1 × 105 pfu of CV and sacrificed 
at the indicated points in time. (E) Heart tissue was homogenized and subjected to Western blot analysis for detection of ISG15. Each lane represents tissue obtained from 
a different animal, and the shown example for each group and point in time is representative for n = 3 mice. (F) At day 6 after infection, infectious viral particles were 
determined in heart by TaqMan qPCR and plaque assay. Each dot represents a different animal. Data are summarized as means ± SEM; t tests were performed, and P values 
of <0.05 are depicted. (G) Cardiomyocytes derived from USP18C61A ISG15−/− and ISG15−/− embryos were transduced with Ad5 vectors encoding murine ISG15 and stim-
ulated with poly(I:C). Cellular lysates were subjected to Western blot analysis. (H to J) ISG15-rescued cardiomyocytes from USP18C61A ISG15−/− and ISG15−/− embryos 
were infected with CV at an MOI of 0.1 for 24 hours. (H) Total RNA was isolated to determine CV genome copy numbers by TaqMan qPCR; Ct values obtained from 
duplicates are shown for two independent experiments. Data are summarized as means ± SEM. (I) Viral load was determined in cellular lysates by Western blot analysis of 
CV VP1. Densitometric analysis of VP1 and the GAPDH loading control was performed to calculate the mean (± SEM) relative VP1 expression in three independent exper-
iments. (J) Release of infectious viral particles was assessed by plaque assay. One representative out of three independent experiments yielding the same result is depicted. 
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(IL-6) (36), and several other effector functions of innate myeloid 
cells, such as production of reactive oxygen species (ROS), nitric oxide 
(NO), or phagocytosis, are critical for CV clearance (37), we investi-
gated whether ISG15 affects these processes. We found increased 
mRNA expression levels for IL-6, CXCL10, and CCL2 in both Toll-like 
receptor 3 (TLR3)–activated ISG15−/− bone marrow–derived macro-
phages (BMMs) and CV-infected ISG15−/− mice in comparison to 
wild-type controls (fig. S3, A and B). ROS (fig. S3, C and D) and NO 
(fig. S3E) production, mediated by TLR3, were similar in BMM re-
gardless of whether they were derived from wild-type or ISG15−/− 
mice. We used three different approaches to investigate the role of 
ISG15 on the phagocytotic capacity of BMM and found that ISG15 
had no effect on phagocytosis (fig. S3F). To gain a closer insight into 
the biological role of ISG15 in hematopoietic-derived immune cells 
during CV infection, we generated ISG15−/− bone marrow chimeras. 
Lethally irradiated ISG15−/− mice were reconstituted with bone 
marrow cells obtained from either wild-type or ISG15−/− mice (fig. 
S3G). Analysis of ISG15−/− recipients showed that CV titers in the 
liver, pancreas, spleen, and heart were identical in mice that were 
reconstituted with wild-type bone marrow cells (wild-type ➔ ISG15−/− 
chimeras) or with ISG15−/− bone marrow cells (ISG15−/− ➔ ISG15−/− 
chimeras) (Fig. 2A). We found that depletion of ISG15 in bone 
marrow–derived hematopoietic cells had no influence on the pro-
duction of IL-6 and of CXCL10 and CCL2, as indicated by equal 
levels of mRNA expression of the respective cytokines in the spleen 
3 days after infection (Fig. 2B). Collectively, our data show that 
ISG15 in immune cells is not required for control of CV infection.
On the basis of these findings, we hypothesized that ISG15 
mediates protection from CV pathology by protein ISGylation in 
nonhematopoietic cell types and tissues. To test this hypothesis, we 
generated Ube1L−/− and wild-type bone marrow chimeras. When-
ever lethally irradiated wild-type recipients were reconstituted with 
bone marrow cells from Ube1L−/− mice (Ube1L−/− ➔ wild-type), we 
obtained mice where protein ISGylation could be triggered in non–
bone marrow–derived somatic cell types and tissues only but not 
in hematopoietic-derived immune cells. Alternatively, in Ube1L−/− 
chimeras reconstituted with bone marrow cells from wild-type mice 
(wild-type ➔ Ube1L−/−), protein ISGylation could be exclusively 
induced in hematopoietic-derived immune cells. Because of a dele-
tion of the E1-activating enzyme Ube1L, ISGylation was not possible 
in non–bone marrow–derived cells (fig. S4). Infection studies using this 
experimental setup and respective controls (wild-type ➔ wild-type 
and Ube1L−/− ➔ Ube1L−/−) allowed us to distinguish whether 
ISGylation in non–bone marrow–derived somatic cell types is re-
quired for suppression of CV-mediated tissue injury. Upon infec-
tion of these chimeras, CV titers were found to be increased in the 
hearts of Ube1L−/− mice that had been reconstituted with bone marrow 
cells from Ube1L−/− mice (Ube1L−/− ➔ Ube1L−/−) when compared 
to wild-type mice reconstituted with bone marrow cells from wild-type 
mice (wild-type ➔ wild-type) (Fig. 2C). The increased CV load 
found in Ube1L−/− ➔ Ube1L−/− mice resulted in high-grade inflam-
mation and tissue destruction of the heart (Fig. 2, D and E), as well as 
increased chemokine expression (Fig. 2F). These results demonstrate 
the protective role of protein ISGylation to mitigate CV-triggered 
pathology. As demonstrated by equally high viral titers in Ube1L−/− 
chimera reconstituted with wild-type bone marrow cells (wild-type➔ 
Ube1L−/−), the aggravated phenotype detected in Ube1L−/−➔ Ube1L−/− 
mice was not improved once immune cells were equipped with an 
operative ISGylation machinery (Fig. 2, C to F). This argues against 
Fig. 2. Protection from CV pathology requires ISGylation in nonhematopoietic 
cells. (A and B) ISG15−/− (CD45.2) mice were reconstituted with bone marrow cells 
from either ISG15−/− (CD45.2) or wild-type (wt, CD45.1) donors before CV infection, and 
mice were sacrificed 3 days after infection. (A) Infectious viral particles were quanti-
fied by plaque assay (wild-type ➔ ISG15−/−, n = 6; ISG15−/− ➔ ISG15−/−, n = 4). Data 
are summarized as median. (B) Splenic mRNA expression of the indicated cytokines 
and chemokines was determined by TaqMan qPCR. (C to F) Chimeric wild-type and 
Ube1L−/− mice were generated upon transfer of wild-type or Ube1L−/− bone marrow 
cells into lethally irradiated wild-type or Ube1L−/− recipients, respectively. Mice were 
infected with CV and sacrificed after 8 days (n = 7 in all four groups). (C) Infectious 
viral particles were quantified in heart tissue by plaque assay. Data are summarized 
as means ± SEM. (D) Myocarditis was scored microscopically by a blinded pathologist 
based on cardiac hematoxylin and eosin staining. (E) Representative histopathologic 
stains of heart tissue of each group are shown. (F) mRNA levels of the indicated 
genes in heart tissue were determined by TaqMan qPCR. Unequal variance versions 
of two-way ANOVA were performed, followed by a Sidak-Holm’s multiple comparison 
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a biological role of protein ISGylation in bone marrow–derived 
immune cells during CV infection. Vice versa, in comparison to 
wild-type ➔ wild-type mice, knockdown of the E1-activating enzyme 
Ube1L specifically in bone marrow cells (Ube1L−/− ➔ wild-type) had 
no effect on CV titers or on inflammatory injury (Fig. 2, C to F). 
Together, our data demonstrate that ISGylation in non–bone marrow–
derived somatic cell types is essential to prevent viral cytotoxicity 
and inflammatory tissue damage during CV infection.
ISGylation increases expression levels of IFIT1/3 proteins
To identify molecular mechanisms involved in how protein ISGylation 
suppresses the viral titer in cells targeted by viral infection, we per-
formed protein profiling on infected liver tissue using mass spectrom-
etry (MS)–based proteomics. In line with published data (32, 38), 
our proteomics analysis confirmed that, in addition to ISG15, 
IFN-induced proteins with tetratricopeptide repeats (IFIT) 1 and 
3 are among the most intensively up-regulated proteins during CV 
infection (Fig. 3A). Because different ISGs often act cooperatively 
(39) and IFIT proteins are required for control of CV infection (32), 
our analysis focused, in particular, on these antiviral effectors. 
Notably, an MS–based search for ISG15 substrates in HeLa cells 
identified IFIT family proteins as targets of ISG15 (13, 40). On the 
basis of this, we tested ISGylation of IFIT proteins and performed 
pull-down experiments using cellular lysates from IFN-–treated 
FLAG-ISG15-HeLa cells. Higher molecular weight versions of 
IFIT1 and IFIT3 proteins were detected within the pool of enriched 
ISGylated proteins (Fig. 3B), which appeared to be ISGylation of 
IFIT1 and IFIT3. To be sure, we transfected FLAG-tagged IFIT1/3 
into HeLa cells along with ISG15 and plasmids encoding the E1/E2/E3 
proteins. Pull down of both IFIT1 and IFIT3 revealed higher molec-
ular weight versions of both IFIT proteins, thereby confirming 
ISGylation of IFIT1 and IFIT3 (Fig. 3C).
To explore the proposed additive activity of ISG15 and IFIT pro-
teins, we investigated how ISG15 alters IFIT1/3 protein expression, 
if at all. We used ISG15-ko HeLa cells generated by CRISPR-Cas9–
mediated gene editing. Stimulation of the IFNAR (interferon-/ 
receptor) induced higher IFIT1/3 transcript levels in ISG15-ko HeLa 
cells compared to wild-type controls (Fig. 3D). In clear contrast, the pro-
tein expression levels of IFIT1 and IFIT3 were increased in wild-type 
cells, which did not reflect increased transcript levels found in ISG15-ko 
cells (Fig. 3E). Using FLAG-tagged IFIT1/3 complementary DNA 
(cDNA) constructs in the same cell culture model, we obtained similar 
results, confirming profoundly increased IFIT1/3 protein expression 
in wild-type cells in comparison to ISG15-ko HeLa cells (Fig. 3F). 
Moreover, small interfering RNA (siRNA)–mediated knockdown of 
ISG15 in HeLa cells resulted in decreased IFN-induced IFIT1/3 ex-
pression in comparison to control cells (fig. S5). To explore whether 
reduced protein expression of IFIT1/3 in ISG15−/− cells can be re-
stored by ISG15, we investigated IFIT protein expression in ISG15-ko 
cells, with and without the restoration of ISG15 by exogenous ISG15 
expression. Again, induction of ISG15/ISGylation resulted in in-
creased IFIT1 and IFIT3 protein expression levels (Fig. 3G), thereby 
proving ISG15-mediated increased expression of IFIT1/3 proteins 
at the posttranscriptional level.
Our finding that ISG15 increases protein expression levels for 
IFIT1/3, despite reciprocal effects on IFIT transcription, prompted 
us to question whether the stabilizing effect of ISG15 on IFIT1/3 
protein expression involves ISGylation. To verify a role for ISGylation 
relating to IFIT expression levels, we transfected ISG15-ko HeLa cells 
with either hISG15-LRGG (wild-type) or an unconjugatable hISG15-
LRAA mutant. IFIT protein expression was induced in these cells, and 
we found higher IFIT1 and IFIT3 protein expression levels in cells with 
an operative ISGylation machinery compared to cells expressing 
hISG15-LRAA mutants (Fig. 3H), confirming that ISGylation in-
creases IFIT1 and IFIT3 protein expression. Further supportive evi-
dence for a specific contribution of ISGylation to IFIT1/3 protein 
expression comes from cell culture experiments using primary cardio-
myocytes from USP18C61A ISG15−/− mice. Both USP18C61A 
ISG15−/− and ISG15−/− cells were resupplied with ISG15 activity 
by adenoviral transduction to trigger ISGylation with detection of 
higher ISGylation levels in cells from USP18C61A ISG15−/− mice. 
Upon induction of IFIT1/3 expression by IFN, the expression levels 
of IFIT1/3 were elevated in ISG15-reconstituted USP18C61A ISG15−/− 
cells compared with ISG15−/− cells (Fig. 3I), thereby verifying the 
stabilizing role of ISGylation on IFIT1/3 proteins. Together, our find-
ings prove that the ISG15 system controls protein expression levels 
for IFIT1/3 at posttranscriptional level through its capacity to form 
covalent protein conjugates.
ISG15 reprograms central liver metabolism  
during CV infection
Viral infection with the subsequent activation of host defense path-
ways alters the cellular demands for ATP, requiring remodeling 
of central metabolic processes (29, 41). In addition, we found that 
HeLa cells infected with CV increased their glucose consumption, 
showing, together with a higher release of lactate, elevated glycolysis 
rates in infected cells. Compared to control cells, glucose consump-
tion and release of lactate were significantly increased in infected 
ISG15-ko HeLa cells (Fig. 4A). IFN treatment, which inhibits CV 
replication in cell culture studies (32), decreased glucose consump-
tion back to control levels in both wild-type and ISG15-ko cells 
(Fig. 4A). In the context of a whole organism, in addition to elevated 
glucose uptake by infected cells, alternative mechanisms such as an 
impaired function of the exocrine pancreas (42) may substantiate 
the requirement for metabolic reprogramming after CV infection. 
We found a significant decline of blood glucose and triglyceride 
concentrations after CV infection in both wild-type and ISG15−/− 
mice (Fig. 4B). Free fatty acids (FFAs), reflecting mobilized sources 
of stored triglycerides, also declined (Fig. 4B). We quantified glucose 
and its branched storage form in the liver and found a significant 
reduction of both glucose and glycogen after CV infection (Fig. 4, 
C and D), providing further evidence for infection-triggered hypo-
glycemia. Together, these findings indicate that, after CV infection, 
mice acquire a hypoglycemic state with an increased energy demand 
accompanied with a malnutrition phase and lower glucose store 
in the liver.
A comparison of glucose and glycogen in blood and liver of 
ISG15−/− mice and wild-type controls revealed a hypoglycemic state 
in ISG15−/− mice already before infection (Fig. 4B), reflected by both 
a reduced blood glucose level and a lower glycogen and glucose 
content in the liver (Fig. 4, C and D). Early after CV infection, blood 
and liver glucose declined to lower levels in ISG15−/− mice with a 
substantially reduced glycogen content in liver tissue compared to 
wild-type mice, demonstrating a role of ISG15 for glucose homeo-
stasis in CV infection. To obtain more insights into the function of 
ISG15 on central liver metabolism during infection, we investigated 
how CV infection affects the protein abundance of key metabolic 
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Fig. 3. ISGylation increases expression levels of IFIT1/3 proteins. (A) Liver samples obtained from wild-type (wt) mice (n = 3) before and 3 days after infection were sub-
jected to LC-MS/MS analysis. In the depicted volcano plots, each protein identified at baseline and after CV infection in the proteome screen of liver tissue is represented 
by a dot. The x axis specifies log2 fold changes and the y axis specifies −log10 of P values obtained from t test. (B) 3×FLAG-6×His-ISG15-HeLa cells and controls were stim-
ulated with IFN- for 24 hours, and cellular lysates were subjected to FLAG immunoprecipitation (IP). Total cell lysates (input) and FLAG-IP enriched proteins were immuno-
blotted using antibodies for ISG15, IFIT3, and IFIT1. Data are representative of three independent experiments. (C) HeLa cells transfected with a four-plasmid combination 
(HA-ISG15, Ube1L, Ube2L6, and Herc5) and with either FLAG-tagged IFIT1 or IFIT3 were subjected to pull-down experiments using anti-FLAG agarose beads. Total cell 
lysates and FLAG-immunoprecipitated proteins were subjected to immunoblotting using antibodies for FLAG and HA. Data are representative of three independent ex-
periments. (D and E) ISG15-ko HeLa cells generated by CRISPR-Cas9–mediated gene editing and respective control cells were stimulated with IFN- (100 U/ml). IFIT1/IFIT3 
transcripts and IFIT1/IFIT3 protein expression levels were determined by (D) TaqMan qPCR and (E) Western blot analysis. One represent ative of three independently 
performed experiments is shown. Unpaired t tests were conducted. (F) ISG15-ko HeLa cells and controls were transfected with plasmids encoding either FLAG-tagged 
IFIT1 or IFIT3, and IFIT expression was determined by Western blot analysis. Date are representative of three independent experiments. (G) ISG15-ko HeLa cells were 
transfected with either GFP or ISG15 cDNA together with IFIT1 or IFIT3 expression plasmids, respectively. Subsequently, cells were stimulated with IFN- for 24 hours, and 
IFIT protein expression levels were determined by Western blot analysis. Data are representative of two independent experiments. (H) Following the experimental ap-
proach outlined in (G), ISG15-ko cells were transfected with either ISG15 or the unconjugatable ISG15-LRAA mutant as well as with IFIT1/3 cDNA. IFIT protein expression 
was determined after 24 hours by Western blot analysis. Data are representative for three independent experiments. (I) Primary cardiomyocytes were generated from 
USP18C61A ISG15−/− and ISG15−/− mice, and ISGylation was induced by transduction of Ad5 vectors encoding mISG15. Cells were left unstimulated or stimulated with 
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Fig. 4. ISG15 influences the metabolic state in healthy mice and during CV infection. (A) Unstimulated or IFN- pretreated, ISG15-ko HeLa, and control cells were 
infected with CV (MOI 1.0). After 32 hours, the glucose and lactate concentrations were determined in cell culture supernatants. Values normalized to cell counts per well 
are presented as increase relative to the untreated wild-type control. The data of four independent experiments have been summarized as means ± SEM. A two-way 
ANOVA test was performed followed by a Sidak’s multiple comparison test. (B to D) Wild-type (wt) and ISG15−/− mice sacrificed before (wild-type, n = 7; ISG15−/−, n = 7), 
3 days (wild-type, n = 8; ISG15−/−, n = 6), and 8 days (wild-type, n = 9; ISG15−/−, n = 8) after CV infection. (B) Blood glucose and serum triglycerides/FFAs at baseline and 
3 and 8 days after CV infection in wild-type and ISG15−/− mice summarized as the means ± SEM. Numbers in bar graphs are the percentage of the metabolite compared 
to the mean value in naive wild-type mice. Multiple t tests with Holm-Sidak multiple comparison correction were performed. (C) Glycogen content visualized in liver 
tissue section with periodic acid Schiff reaction. Representative images are shown. (D) Glycogen content scored semiquantitatively from 0 to 4 based on histological 
analysis and glucose concentration assessed in liver tissue homogenates. Bars are means ± SEM. Multiple t tests with Holm-Sidak multiple comparison correction were 
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Quantitative proteomic data were obtained from shotgun liquid 
chromatography–tandem MS (LC-MS/MS) analysis of liver samples 
derived from wild-type and ISG15−/− mice at baseline as well as 3 and 
8 days after infection. Using a label-free quantitative setup, 3982 pro-
teins were identified by LC-MS/MS analysis, of which 1094 proteins 
were found to be significantly up- or down-regulated. Cluster analysis 
revealed six distinct protein profiles in both wild-type and ISG15−/− 
mice during CV infection (Fig. 5A). A direct comparison of the dif-
ferent protein clusters revealed up to 73% of the identified proteins 
to be regulated differentially in wild-type and ISG15−/− mice (fig. 
S6A). Gene Ontology (GO) enrichment analysis of these clusters un-
covered a reduction of proteins involved specifically in FA oxidation 
and oxidative phosphorylation (OXPHOS) in the absence of ISG15 
at an early stage of infection. In wild-type mice, these alterations of 
protein levels were only observed in later stages of infection (Fig. 5B). 
Enzymes of carbohydrate metabolism involving key enzymes of 
glycolysis, such as fructose-1,6-bisphosphate-aldolase, pyruvate 
kinase, or lactate dehydrogenase, were up-regulated in wild-type 
mice at this advanced state of infection (Fig. 5B).
As a next step, we investigated whether these altered protein 
abundances of metabolic enzymes or proteins regulating OXPHOS 
and carbohydrate metabolism in ISG15−/− mice influence mito-
chondrial metabolism of liver tissue during CV infection. We used 
the Seahorse metabolic assay platform to monitor both the oxygen 
consumption and extracellular acidification rate as parameters for 
mitochondrial metabolism in liver biopsies obtained from ISG15−/− 
mice and wild-type controls 3 and 8 days after CV infection. Three days 
after CV infection, liver tissue of wild-type mice had a higher oxygen 
consumption and extracellular acidification rate compared to un-
infected controls; however, both parameters remained at baseline 
levels in ISG15−/− mice at this stage (Fig. 5C). After 8 days, oxygen 
consumption and extracellular acidification rate reached baseline levels 
in wild-type mice, with no alteration found in ISG15−/− mice (Fig. 5C). 
Together, these functional data show that ISG15 activates oxidative 
mitochondrial metabolism in liver tissue early after CV infection.
Although alterations in enzyme abundances as detected by 
LC-MS/MS analysis and functional investigation of liver tissue by 
Seahorse technology deliver substantial information on specific met-
abolic reactions, the biomedical challenge is to integrate these data 
into a modeling platform that enables in silico prediction of organ 
metabolism. To determine how ISG15 affects liver metabolism 
during CV infection, we integrated various effectors of metabolism 
by computing proteome data for metabolic enzymes during CV in-
fection using HEPATOKIN1, a multiscale kinetic model of central 
liver metabolism (43). First, we assumed a 24-hour standard metab-
olite profile to compute the mean diurnal metabolic effort of different 
metabolic pathways after infection under standardized conditions. 
Our simulations show that the metabolic alterations progress during 
the stages of CV infection. In line with the aforementioned findings 
in the GO enrichment analysis, FA oxidation increases specifically 
in wild-type mice during the early phase of CV infection. FA syn-
thesis rates were reduced during infection, yielding similar values 
in naive controls and 3 days after infection in both wild-type and 
ISG15−/− mice, respectively (fig. S6B). Glucose production in wild-type 
controls maintained at baseline levels early upon infection, whereas 
these processes were reduced in ISG15−/− mice, revealing a lower 
capacity for hepatic glucose production in the absence of ISG15 
(Fig. 5D and fig. S6B). After 8 days, the glycolytic capacity of liver 
tissue increased in both wild-type and ISG15−/− mice. This adaptation 
of carbohydrate metabolism was more pronounced in wild-type mice 
(Fig. 5D and fig. S6B). Overall, these data demonstrate that ISG15 
influences the central liver metabolism at the different stages of CV 
infection by increasing the capacity of liver tissue for endogenous 
glucose production during the early stage and by equipping the liver 
with an enzymatic machinery needed for efficient glycolysis at later 
stages of CV infection.
We used the metabolic model to investigate how ISG15 affects 
exchangeable metabolites in liver tissue before and during infection 
for strain- and disease-specific stage conditions. Instead of standard-
ized conditions, we used experimentally determined blood glucose 
levels as the data input into the model to determine the metabolic 
response of the liver in both wild-type and ISG15−/− mice in terms 
of glucose and FA exchange flux as well as hepatic glycogen content 
(Fig. 4C). Under baseline conditions, we found that the healthy liver 
of wild-type control mice is a net consumer of glucose. At 170 mg/ml, 
which is the mean nonfasting blood glucose detected in this group 
(Fig. 4B), the liver consumes glucose with a computed rate of 
69 mol g−1 hour−1 (Fig. 5E and fig. S6C). In contrast, naïve ISG15−/− 
mice are not net glucose consumer but instead produce glucose at a 
rate of 38 mol g−1 hour−1 under baseline conditions. A 50% reduction 
of the glycogen content in liver tissue of ISG15−/− mice calculated by 
metabolic modeling (Fig. 5E) corresponds to the lower glycogen 
store shown by histologic examination of liver tissue from hypogly-
cemic ISG15−/− mice (Fig. 4, C and D). Early after CV infection (day 3), 
when blood glucose levels drop significantly (Fig. 4B), the liver re-
sponds with a pronounced shift toward glucose production, partic-
ularly in wild-type mice. The computed glucose production rate by 
liver tissue was 66 mol g−1 hour−1 in wild-type mice and 55 mol 
g−1 hour−1 in ISG15−/− mice (Fig. 5E and fig. S6C). Eight days after 
infection, when blood glucose levels remain hypoglycemic but 
gradually shift back to normal (110 mg/ml in wild-type mice and 
93 mg/ml in ISG15−/− mice; Fig. 4B), the rates of gluconeogenesis 
decrease slightly (42 mol g−1 hour−1 in wild-type mice and 44 mol 
g−1 hour−1 in ISG15−/− mice). The computed glycogen content of 
liver tissue was reduced during CV infection, corresponding to 
experimental findings 3 and 8 days after infection. Carbohydrate 
metabolism in liver tissue is closely linked to FA metabolism. 
During CV infection, the catabolic phase of acute viral infection is 
accompanied by reduced levels of FFA in mouse serum (Fig. 4B), 
reflected by the increase in uptake of FA by liver tissue (Fig. 5E). 
Compared to wild-type mice, ISG15−/− mice had a higher uptake 
of FA by liver tissue during CV infection (Fig. 5E). In conclusion, 
ISG15 ensures efficient storage of glucose in liver tissue of healthy 
mice and reprograms liver metabolism toward greater glucose pro-
duction early after CV infection.
Identification of the antiviral capacity of  
human ISG15 for CV infection
Our finding that inactivation of the ISG15-specific protease USP18 
renders cells more resistant to CV infection (Fig. 1, E to J) strongly 
suggests that stabilizing ISGylation by USP18 inhibition could be 
exploited therapeutically. Therefore, we asked whether the antiviral 
activity of ISGylation observed in the mouse also applies to the 
human system. First, CV-permissive HeLa cells, in which ISG15 ex-
pression was shut down by CRISPR-Cas9 gene editing, were used to 
explore the role of human ISG15 during CV infection. Viral replication, 
as monitored by the detection of both the CV structural protein VP1 
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Fig. 5. ISG15 reprograms the central liver metabolism during CV infection. (A) Hepatic tissue obtained from wild-type (wt) and ISG15−/− mice (n = 3) during early 
(day 3) and late (day 8) state of CV infection was subjected to LC-MS/MS analysis. Heatmaps summarizing all differentially regulated hepatic proteins during infection for 
both strains are depicted. The relative abundance of each protein is color-coded based on the z score normalized log2-transformed LFQ intensities. Blue color indicates 
proteins of high abundance, and yellow color indicates proteins of low abundance as compared to row means. A hierarchical clustering resolved six distinct clusters, with 
annotation shown on the right. (B) Heatmap-based clusters were subjected to Gene Ontology (GO) analysis, and proteins involved in selected enriched metabolic GO 
terms with catabolic ATP-generating function (FA oxidation, carbohydrate catabolic process, and OXPHOS) are depicted at an early and late state of CV infection, applying 
the same color code as used in (A) (blue, up-regulation; yellow, down-regulation). If the GO term of interest was not found within a dataset, individual proteins were not 
plotted. (C) At the indicated time points of infection, liver biopsies were obtained from wild-type and ISG15−/− mice. The basal oxygen consumption (top) and extracellular 
acidification (bottom) rates were monitored using a Seahorse Biosciences extracellular flux analyzer. Values were normalized to protein content in the biopsies. Data of 
at least six mice per group were summarized as means ± SEM. A one-way ANOVA was performed followed by a Tukey’s multiple comparison test. (D and E) Liver proteome 
data together with HEPATOKIN1, a model of central liver metabolism (43), were used to assess the metabolic alterations in liver tissue of wild-type and ISG15−/− mice 
during viral infection. Metabolic models for the different conditions were constructed by scaling the maximal activity for each enzyme using the LFQ intensities for each 
protein obtained from MaxQuant analysis at the respective point in time. (D) For a standard 24-hour profile metabolite plasma profile, diurnal glucose exchange fluxes 
were simulated in wild-type and ISG15−/− mice at each time point of viral infection. Negative exchange fluxes indicate net release from the liver to the plasma (gluco-
neogenesis), while positive values indicate hepatic glucose uptake (glycolysis). (E) For each condition, experimentally determined blood glucose levels as depicted in 
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to control cells (Fig. 6A). Correspondingly, a transient knockdown 
of ISG15 achieved by siRNA technology resulted in higher VP1 
production in infected cells (Fig. 6B). In a reverse approach, HeLa 
cells with stable ISG15 overexpression (3) were infected with CV, 
resulting in reduced VP1 protein expression levels in comparison to 
control cells (Fig. 6C). In a complementary approach, human ISG15 
was transduced into primary cardiomyocytes obtained from ISG15−/− 
mice, and together with ISG15−/− controls, these human ISG15- 
expressing cells were infected with CV. Cells expressing human 
ISG15 showed a significantly decreased production of VP1 and a 
Fig. 6. Human ISG15 suppresses CV replication. (A) ISG15 expression was deleted in HeLa cells using CRISPR-Cas9 gene editing as described in Fig. 3. ISG15-ko cells and 
wild-type cells were infected with CV (MOI 0.1) for 16 hours. Expression of CV VP1 was determined by Western blot analysis in four independent experiments, and the 
obtained signal normalized to GAPDH was compared to wild-type samples. Infectious virus particles were quantified in five independent experiments by plaque assay. 
Data are summarized as means ± SEM. (B) HeLa cells were transfected with siRNA targeting human ISG15 or a nontargeting control siRNA. Cells were subsequently infected 
with CV (MOI 0.01) for 16 hours. VP1 protein expression was determined and normalized to the control sample in four independent experiments. Plaque assays were 
performed in two independent experiments. Data are summarized as described in (A). (C) HeLa cells stably expressing FLAG-tagged human ISG15 and respective control 
cells were infected with CV (MOI 0.1) for 16 hours. VP1 expression and virus titer were determined as described in (A) in three independent experiments. (D) Primary embryonic 
cardiomyocytes obtained from ISG15−/− mice were transduced with Ad5 vectors expressing human ISG15 (hISG15) or control for 48 hours at MOI 25 before CV infection 
(MOI 0.1) for 24 hours. VP1 levels were determined by Western blot analysis, and infectious viral particles were quantified by plaque assay in three independent experi-
ments. (E) Cardiomyocytes derived from USP18C61A ISG15−/− and ISG15−/− embryos were transduced with Ad5 vectors encoding hISG15 and infected with CV in three 
independent experiments for detection of the viral load by Western blot analysis of VP1 as well as plaque assay. One-sample t tests were performed for all summarized 
VP1 data. Unpaired t tests were conducted for all plaque assay data. (F and G) CVB isolates were obtained from patients presenting with neurological symptoms that may 
have been of infectious origin. (F) ISG15-ko HeLa cells and control cells were infected with the indicated CV serotypes (MOI 0.1), and infectious virus particles were deter-
mined after 16 hours by plaque assay. The relative increase of the viral titer in ISG15-ko HeLa cells as compared to control cells is depicted for a representative experiment. 
Three independent experiments demonstrated similar results. (G) The ISG15 system was induced in USP18C61A ISG15−/− and ISG15−/− cardiomyocytes by transduction of 
Ad5 vectors encoding hISG15. Cells were infected with CV serotypes as follows: CVB1 425, MOI 1 (2 days); CVB1 506, MOI 1 (1 day); CVB3 1072, MOI 10 (2 days); CVB3 180, 
MOI 10 (1 day); CVB4 686, MOI 10 (2 days); CVB4 120, MOI1 (2 days); CVB5 679, MOI 1 (1 days); CVB5 800, MOI 10 (1 day). Infectious viral particles were quantified by plaque 
assay. Relative reduction of the viral load in USP18C61A ISG15−/− cells as compared to ISG15−/− cardiomyocytes with restored ISG15 expression is depicted for a representative 
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lower virus titer (Fig. 6D). Last, we asked whether inactivation of the 
ISG15-specific protease USP18, achieved by the C61A mutation (9), 
might be used to increase the antiviral activity exerted by human 
ISG15. Therefore, ISGylation was restored in cardiomyocytes ob-
tained from USP18C61A ISG15−/− or ISG15−/− mice by adenoviral 
vector transduction of human ISG15, resulting in hyper-ISGylation 
in USP18C61A ISG15−/− cells. After CV infection, as reflected by 
both profoundly reduced VP1 production and lower viral titer in 
USP18C61A ISG15−/− cardiomyocytes with reconstituted hISG15 
expression, enhanced linkage of human ISG15 to target proteins 
conferred increased antiviral activity (Fig. 6E). Together, these 
results show that there is no particular human/mouse species barrier 
in the role of ISGylation counteracting CV infection.
Targeting ISGylation as an antiviral approach for  
clinical CVB isolates
Our results demonstrated that ISGylation is an effective antiviral 
effector operative on a laboratory CV strain. Because a laboratory 
viral strain might differ from clinically relevant viruses, we tested 
the latter for their sensitivity to ISG15. Two isolates of the CV sero-
types CVB1, CVB2, CVB3, and CVB5 were obtained from patients 
undergoing clinical investigation due to suspected meningitis or 
encephalitis. To investigate whether ISG15 influences the replication 
of these CVB serotypes, after virus propagation in cell culture, we 
infected ISG15-ko HeLa cells and wild-type controls with the clinical 
strains. This approach enabled us to study the effect mediated by 
ISG15 expression under baseline conditions, because ISG15 is in-
duced neither by CV infection nor by IFN before infection, as this 
would completely block the replication of CV (27). After two replica-
tion cycles, viral titers were determined for each serotype by plaque 
assay. As depicted in Fig. 6F, in comparison to wild-type cells, we 
found an increased viral load in ISG15-ko cells for one of the CVB5 
and both of the CVB1 and CVB4 isolates, confirming an antiviral 
activity of human ISG15 for these clinical CV strains. This finding 
prompted us to evaluate whether a therapeutic strategy of enhancing 
ISGylation might be used for the clinical CVB serotypes. Therefore, 
we made use of our cell culture system, isolating USP18C61A ISG15−/− 
and ISG15−/− cardiomyocytes and restoring ISGylation by adenovirus 
vector–mediated transduction of human ISG15, as outlined above 
(Fig. 6E). After triggering hyper-ISGylation in cells from USP18C61A 
ISG15−/− and ISGylation in cells from ISG15−/− mice, cells were in-
fected with the CVB1, CVB2, CVB3, and CVB5 serotypes, and viral 
titers were determined by plaque assay. Hyper-ISGylation originat-
ing from USP18 protease inactivation significantly reduced the viral 
load for all CV serotypes, with some strains being more vulnerable 
to this approach than others, yielding an overall reduction of viral 
titers to 18.1 ± 4.8% in comparison to control cells (Fig. 6G). In con-
clusion, enhancing ISGylation inhibited the replication of all clinical 
CV isolates tested.
DISCUSSION
The findings of our study are briefly summarized in Fig. 7. Our data 
indicate that ISG15 inhibits viral cytotoxicity during CV infection 
by suppressing the viral burden both at an early stage in liver, pancreas, 
and spleen as well as at later stages in heart tissue, thereby mitigating 
viral pathology and attenuating inflammatory tissue damage. Our 
results demonstrate that protein ISGylation is required in nonhema-
topoietic cells to promote cellular resistance to CV infection. Both 
ablation of the ISG15 gene and deficiency of the E1 enzyme Ube1L 
increased viral titers equally at the different stages of CV infection. 
This finding emphasizes the physiological requirement of ISGylation 
in vivo, an important aspect regarding the increasing number of 
reports on various immunomodulatory functions of free ISG15 and 
their protective role in infectious disease (1). ISG15, in its unconju-
gated form, activates IFN- production by NK cells (4, 20). However, 
IFN- secretion by NK cells is not affected in Ube1L−/− mice, which 
express free ISG15 but are ISGylation incompetent (21). Apart from 
an advanced stage of pancreatic injury (day 6), Ube1L−/− mice ex-
hibited the same CV pathology as ISG15−/− mice. The finding that 
viral titers are higher in ISG15−/− mice in comparison to both wild-
type and Ube1L−/− mice in the pancreas at day 6 might be indic-
ative of a contribution of free ISG15 to combating CV infection. On the 
other hand, viral cytotoxicity attacks the pancreas as early as between 
day 1 and day 2 after infection (25), and Ube1L−/− mice showed 
similarly increased viral titers as ISG15−/− mice 3 days after infection. 
Therefore, we conclude that free ISG15-triggered IFN- release by 
NK cells is of minor biological relevance in counteracting CV-triggered 
pathology. Moreover, ISG15 influences other functions of innate 
immune cells, such as phagocytosis and cytokine production by 
macrophages (17, 18). Together with their progenitors, these immune 
cells profoundly aggravate CV-triggered inflammatory pathology 
(37). Most data on the role of ISG15 in macrophages during viral 
infection are derived from in vitro infection studies with vaccinia 
virus, where ISG15-triggered reprogramming of macrophages combats 
Fig. 7. Protein modification with ISG15 acts cooperatively with IFIT proteins 
and preserves glucose homeostasis. CV infection is a bona fide example for multi-
phasic state infectious disease with primary injury of liver and pancreas followed by 
a second viremia culminating in cardiac damage and chronic tissue damage. Early 
upon infection, IFNs trigger the ubiquitin-like modifier ISG15, which, in a three-step 
enzymatic cascade, forms covalent linkages with proteins in both infected and non-
infected cells. In non–bone marrow–derived somatic cells and tissues, ISGylation inhibits 
viral replication, and this involves augmented protein expression levels of antiviral 
effectors such as IFIT1 and IFIT3. ISG15 ensures efficient storage of glucose in liver 
tissue of healthy mice and reprograms liver metabolism toward improved glucose 
production early after CV infection. Cells lacking activity of the ISG15-specific protease 
USP18 show a marked increased resistance against CV infection, thus providing a 
rationale that USP18 inhibition could be a novel host-directed approach countered 
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the infection (17, 18). Other reports provide evidence that protein 
ISGylation exacerbates inflammatory responses (3, 16). In accordance 
with studies using vaccinia virus (18), here, we demonstrate that 
ISGylation suppresses cytokine production during CV infection. In 
our hands, ISG15 had no effect on phagocytosis, ROS, and NO pro-
duction by macrophages. Moreover, the absence of ISG15 did not 
affect manifestation of experimental autoimmune myocarditis (AM) 
(fig. S8), which is also affected profoundly by chemotactic cytokines 
produced by monocytes/macrophages (44). Correspondingly, the 
various bone marrow chimera experiments shown in this study un-
equivocally attributed the biological activity of ISG15 to ISGylation 
in non–bone marrow–derived cells and tissues. Similar to influenza 
B virus (5), protein ISGylation during CV infection sets nonhema-
topoietic cells into an antiviral state, thereby reducing CV-triggered 
cytotoxicity and consequently inhibiting the production of proin-
flammatory mediators. This differentiates the function of ISG15 
for CV-induced pathology from other IFN-dependent pathogens. 
There are other examples, such as influenza A and Sindbis viruses, 
where ISGylation is protective, but this phenotype is seen regardless 
of pathogen titer (45). During infection with chikungunya virus, how-
ever, ISG15 protects the host from virus-triggered injury of lung 
tissue, independent of its protein modifier function (2).
Second, we demonstrate a mechanistic aspect of how ISGylation 
might enhance cellular resistance to CV infection. The E3 ligase 
Herc5 is associated with polyribosomes; as a result, newly synthesized 
proteins are accessible substrates for ISGylation in a cotranslational 
manner (12). Late in the infection cycle, viral proteins make up the 
main bulk of de novo synthesized proteins. Our previous in vitro 
study demonstrated that ISG15 combats the degradation of the host 
translation initiation factor eIF4G by the viral 2A protease, and this 
was partially attributed to ISGylation of this protease (21), revealing 
one aspect of how ISG15 might protect infected cells from CV-triggered 
cytotoxicity. IFN release after viral infection orchestrates the synthesis 
of antiviral ISGs in both infected and noninfected cells, and ISGylation 
of these host proteins may be an alternate mechanism for ISG15 to 
disrupt viral replication upon infection (1). During CV infection, it 
is plausible that other ISGs, such as the IFIT proteins, are modified 
by ISG15 (14, 46), and we verified that both IFIT1 and IFIT3 are 
targets of ISG15 conjugation. As mediators of antiviral immunity, 
IFIT proteins sequester viral RNA and block viral protein transla-
tion, resulting in suppression of viral titers (47). Here, we demon-
strate that ISG15 strongly increases cellular protein expression levels 
of IFIT1 and IFIT3 by protein ISGylation, which is in line with a 
cumulative activity among the ISGs for improved pathogen control 
(39). Regarding the function of protein ISGylation, the increase caused 
by IFIT1/3 protein expression may contribute to enhanced cellular 
resistance against CV infection. Recent data from the Whitton group 
demonstrate that the IFIT locus is required to limit CVB3 replication 
(32). IFITs play a role in protecting many tissues against CVB3 in-
fection, with an IFN-induced phase of IFIT activity specific for the 
heart. RNA-activated protein kinase (PKR) is another example where 
ISGylation affects the activity of ISGs and prepares as yet uninfected 
cells to better resist infection (14). Further supportive evidence for 
cooperative activity of ISG15 with other ISGs comes from the tran-
scription factor IRF3, where ISGylation prevents ubiquitylation of 
IRF3 and thus stabilizes the protein (48). Because both IFIT1 and 
IFIT3 proteins are substrates of ubiquitylation (49), it is conceiv-
able that a modification of IFIT1/3 proteins with ISG15, as shown 
here, might impair proteasomal processing of degradation-prone 
IFIT proteins. Alternatively, because protein ISGylation is known 
to reduce the overall turnover of ubiquitylated proteins by the pro-
teasome, these processes might also influence IFIT protein expres-
sion levels (16, 48).
Enforced activity of the cellular translation machinery in infected 
and IFN-activated cells is a highly energy demanding process that 
requires an adaption of the host metabolism for the swift produc-
tion of ATP (50). IFN-regulated glycolytic metabolism is important 
for the acute induction of an antiviral response during infection with 
CV (28). Here, we report increased glucose consumption rates by 
CV-infected ISG15-ko cells, demonstrating that ISG15, most likely 
by attenuating CV protein synthesis, influences the magnitude of 
glucose uptake. At the same time, in mice, ISG15 ensures a normo-
glycemic state before infection, resulting in fully loaded hepatic 
glycogen stores, allowing rapid adaptation to hypoglycemia. Hypo-
glycemia in naïve ISG15−/− mice alters liver carbohydrate metabo-
lism, leading to low hepatic glycogen stores and a shift toward glucose 
production. Currently, it is not well understood how, under baseline 
conditions, ISG15 controls blood glucose. Among many factors, the 
efficient uptake of nutrients by the intestine is one variable, promoting 
storage of surplus metabolites. We found that the plasma triglyceride 
level, being an indicator of external supply of nutrients, was not affected 
by ISG15, suggesting that at least the uptake of lipids is not altered 
in ISG15−/− mice. In noninfected cells, we also investigated the mito-
chondrial oxidative metabolism and consumption of glucose and 
found no influence of ISG15 on the demand or on the production of ATP 
(fig. S9). Therefore, future studies focusing on the role of ISG15, for 
example, in the endocrine pancreas, are required to dissect the func-
tion of ISG15 for glucose homeostasis under baseline conditions.
After infection with CV, when the energy expenditure increases 
and hepatic glycogen stores are reduced, a rapid remodeling of central 
liver metabolism becomes important, ensuring the efficient supply 
with metabolites for the whole organism. The increased energy de-
mand of infected and cytokine-activated cells (41) is countered to 
some degree by the diminished uptake of nutrients by CV-infected 
mice (42), resulting in a catabolic state with decreased plasma levels 
of glucose, triglycerides, and FFAs. At this stage, experimental analysis 
of mitochondrial oxidative metabolism and shotgun proteomics 
from liver tissue, in combination with metabolic network modeling, 
revealed that ISG15 profoundly influences the central liver metabolism 
toward enforced production of glucose. Our data demonstrate that 
ISG15 reprograms carbohydrate metabolism in the liver to favor 
glucose production after the initial viremia. Early after infection, 
when blood glucose drops profoundly and gluconeogenesis is essen-
tial, kinetic modeling of liver metabolism showed a reduced capacity 
of liver tissue from ISG15−/− mice compared to wild-type mice to 
produce glucose. The ISG15-deficient liver tissue was less able to 
compensate for the profound hypoglycemia mice developed early 
after infection. These metabolic perturbations in ISG15−/− mice can 
be considered as stressor in the battle against CV. Glucose produc-
tion by the liver is an ATP-consuming anabolic pathway, rendering 
glucose production sensitive to ATP depletion. Corresponding to 
a previous in vitro finding regarding the ISG15-dependent increase 
of the oxygen consumption rate in IFN-stimulated macrophages (17), 
our Seahorse measurements of oxidative metabolism in infected liver 
samples, together with proteomics data and results from metabolic 
modeling, demonstrate that ISG15 shifts OXPHOS toward higher 
oxidative capacity in the liver at an early state of infection. This 
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during infection (41), required for ATP-consuming glucose produc-
tion. In addition to the role of ISG15 for adaptation of OXPHOS, 
ISG15 reduces the energy demands of hepatocytes for other cellular 
processes by lowering both cytokine responses and viral protein 
synthesis in CV-infected liver tissue. All these factors explain why 
hepatocytes with an intact ISG15 system at an early stage of virus- 
triggered hypoglycemia maintain their physiological capacity to 
promote glucose production in response to hypoglycemia by liver 
tissue. After the second viremia, when the catabolic phase is main-
tained in both wild-type and ISG15−/− mice, there is only a marginal 
increase of blood glucose and hepatic glycogen. Persisting hypogly-
cemia at this stage requires a compensation by the liver with higher 
production of glucose. Nevertheless, metabolic modeling under 
standardized conditions at this stage revealed, together with preserved 
gluconeogenesis, an increased glycolytic capacity of liver tissue. In 
keeping with a higher protein abundance of key glycolytic enzymes 
in the presence of ISG15, the metabolic shift toward higher glycolytic 
capacity in the liver is supported by ISG15. Therefore, ISG15 pro-
motes an adaptation of organ-specific metabolism toward lower 
availability of metabolic resources, as reflected by lowered levels of 
plasma metabolites in infected mice at this stage, presumably by the 
enhanced activity of adenosine monophosphate (AMP)–activated 
kinases (28).
Precise demarcation of ISG15 function in antiviral and metabolic 
rewiring tremendously improved our understanding of the ISG15 
system for combating CV infection. Despite this impressive antiviral 
activity for CV, ISG15 is not effective for all viruses (51). A constant 
battle of immune evasion mechanisms by the pathogen and cor-
responding host immune response can result in the evolution of 
resist ance by viruses (52, 53). Supportive evidence for the patho-
physiological relevance of ISGylation for CV control, however, comes 
from experiments in which—similar to influenza B and vaccinia virus 
(9)—inactivation of the ISG15-specific protease USP18 enhanced the 
antiviral capacity of the ISG15 system for clinically relevant CV sero-
types. The deconjugating activity of USP18 is selective for ISG15 (7). 
In clear contrast to the physical requirement of the USP18 protein 
for blocking IFNAR signaling (8), inhibition of the protease activity 
of USP18 maintains IFNAR signaling at basal levels (9). Together 
with the antiviral function that we demonstrate here for human 
ISG15 during CV infection, our data support the notion that USP18 
protease inhibition might be exploited as a host-directed antiviral 
approach to combat CV pathology. Our findings provide a rationale 
for therapeutic application of the ISG15 system for patients with 
severe CV pathology. Targeting host factors, as a means of antiviral 
therapy, is attractive, because the antiviral activity mediated by 
ISGylation involves many potent antiviral effector pathways (1) such 
as IFIT proteins and multiple CV serotypes are affected. While min-
imizing the potential evolution of resistance by the virus as observed 
for many direct antivirals (54), stabilizing ISGylation by USP18 inhib-
itors represents a favorable approach to counter CV pathology in man.
METHODS
Mice
C57BL/6J mice were obtained from in-house breeding pairs. ISG15−/−, 
Ube1L−/−, and USP18C61A/C61A (USP18C61A) transgenic mice (all 
C57BL/6) were originally described elsewhere (9, 33, 51). USP18C61A 
and wild-type littermate controls originated from the offspring of 
USP18C61A/wt × USP18C61A/wt mice. ISG15−/− USP18C61A mice were 
generated by successive cross breeding of ISG15−/− and USP18C61A/C61A 
mice. All mice were kept at the animal facilities of the Charité Uni-
versity Medical Center. If not indicated otherwise, 4- to 6-week-old 
male mice received a single intraperitoneal injection of 1 × 105 
plaque-forming units (pfu) of CV (Nancy strain) (22). Eight days after 
infection, heart tissue was isolated, fixed in HistoFix [1× phosphate- 
buffered saline (PBS), 4% ROTI Histofix] overnight, and embedded 
in paraffin. To visualize cardiac infiltration, cross sections were 
stained with hematoxylin and eosin and judged by a blinded pathologist 
as described elsewhere (21). For induction of AM, ISG15−/− mice 
originally on a C57BL/6 background were backcrossed to an A/J 
background for seven to eight generations. To induce AM, mice 
were subcutaneously immunized with a solution of 150 g of murine 
cardiac TnI-peptide (Peptide Specialty Laboratories, Heidelberg, 
Germany) diluted in complete Freund’s adjuvant, which was 
supplemented with Mycobacterium tuberculosis H37Ra (5 mg/ml) 
(Sigma-Aldrich, St Louis, MO, USA). Injections were repeated after 
7 and 14 days. All experiments investigating AM were conducted in 
Heidelberg. Acid fuchsin orange G (Afog) staining was performed 
to detect collagen deposition. Five sections of each heart were in-
spected in a double-blinded fashion by two independent investigators 
under light microscopy to determine respective inflammation and 
fibrosis scores as described elsewhere (55). This study was carried 
out in accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the German animal welfare 
act, which is based on the directive of the European parliament and 
of the council on the protection of animals used for scientific pur-
poses and follows the Institutional Animal Care and Use Committee 
guidelines. This study conforms to the Berlin and Baden-Württemberg 
state guidelines for animal welfare. The protocol was approved by 
the local authorities for animal welfare in Berlin or Karlsruhe (permit 
numbers: G0279/11, G0272/14, H0076/08, and G161/14). All efforts 
were made to minimize suffering.
Bone marrow chimeras
Six- to 10-week-old female congenic mice with CD45.1 (wild-type) 
versus CD45.2 alleles (Ube1L−/− and ISG15−/− mice) were irradiated with 
10 Gy using a Gammacell 40 exactor (MDS Nordion). Mice received 1 × 
107 bone marrow cells from donor mice upon intravenous injection 
into the tail vein. After 3 to 4 weeks, blood samples were collected 
by facial vein puncture for enumeration of CD45.1- and CD45.2- 
expressing white blood cells. Following red blood cell lysis with 10 mM 
KHCO3, 155 mM NH4Cl, and 0.1 mM EDTA, Fc receptor blocking 
reagent (1:50; Miltenyi) was added for 20 min at 4°C. Cells were 
stained with CD45.1 (A20; BD Biosciences) and CD45.2 (104, BD 
Biosciences) antibodies and acquired on a FACSCalibur flow cy-
tometer (BD Biosciences). Data were analyzed using FlowJo v10.0 
software (Tree Star). To obtain ISG15 chimeric mice, bone marrow 
cells from either ISG15−/− (CD45.2) or wild-type (CD45.1) donors 
were injected into ISG15−/− recipient mice, and after 4 weeks, mice 
were infected with 1 × 105 pfu of CV. Ube1L−/− chimera were generated 
by transfer of wild-type (CD45.1) or Ube1L−/− (CD45.2) bone marrow 
cells into wild-type (CD45.1) and Ube1L−/− (CD45.2) recipient mice 
4 weeks before CV infection (1 × 104 pfu per mouse).
Cell culture
Primary cardiomyocytes were isolated and cultured from embryonic 
mouse hearts at embryonic day 14, yielding >90% troponin I–positive 
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cardiomyocytes at a multiplicity of infection (MOI) of 25 for 48 hours 
to induce ISG15 expression. HeLa cells stably expressing 3×FLAG-
6×His-ISG15 (3) were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 
1% penicillin/streptomycin, and puromycin (2 g/ml). Cells were 
infected with CV (Nancy strain) at the indicated MOI for 1 hour at 
37°C. Clinical isolates of CVB serotypes 1, 2, 3, and 5 were isolated 
from patients with suspected meningitis or encephalitis and passaged 
once on HEp-2 or rhabdomyosarcoma RD cells. Viral titers were 
determined on HeLa cell monolayer by plaque assay. Aliquots were 
stored at −80°C before use. For siRNA studies, HeLa cells (American 
Type Culture Collection) were grown to approximately 70% conflu-
ence and medium was changed to Opti-MEM before transfection. 
Cells were transfected with 25 nM human ISG15 siRNA (L-004235-03; 
Dharmacon) or a nontargeting pool (D0018101005; Dharmacon) using 
Lipofectamine RNAiMAX transfection reagent (Invitrogen). IFIT ex-
pression was induced upon transfection of pcDNA3.1-3×FLAG-IFIT1 
(Addgene) or pcDNA3.1-3×FLAG-IFIT3 (Addgene) plasmids using 
Lipofectamine 2000 (Thermo Fisher Scientific). BMMs were generated 
using L929 cell conditioned medium (LCCM) as a source of granulocyte/
macrophage colony-stimulating factor following procedures described 
recently (25). In brief, bone marrow was passed through 40-m cell 
strainers, centrifuged, resuspended with RPMI 1640, and plated in 60-mm 
dishes. After 24 hours, nonadherent cells were collected and replated in 
10-mm dishes with RPMI 1640 supplemented with 30% LCCM. After 
4 days, fresh BMM growth medium was added. After days 7 to 9, cells 
were plated in RPMI 1640 supplemented with 15% LCCM and used 
for experiments. Flow cytometric analysis of F4/80 and CD11b 
coexpression revealed more than 90% macrophage purity. The ISG15 
system was induced by IFN- (100 U/ml; Roche) or polyinosinic: 
polycytidylic acid (poly(I:C)) (50 g/ml; InvivoGen) for 12 to 24 hours.
ISG15 gene editing using CRISPR-Cas9 technology
Single-guide RNAs (sgRNAs) targeting ISG15 were designed using 
CRISPOR (CRISPOR.tefor.net): 5′-CACCGGAACTCATCTTTG-
CCAGTACAGG-3′ and 5′-AAACGTACTGGCAAAGATGAGTTCC-3′. 
The single-strand gRNAs were duplexed and ligated into the Bsm 
BI–digested and dephosphorylated lentiCRISPRv2 vector. After 
validation of correct sequences, the sgRNA-containing plasmid was 
transfected into human embryonic kidney (Hek) 293 T cells together 
with lentiviral packaging plasmids psPAX2 (Addgene) and pMD2.G 
(Addgene) using polyethylenimine as transfection reagent. The green 
fluorescent protein (GFP) carrying lentiviral plasmid pLJM1-EGFP 
(Addgene) was transfected together with the two packaging plasmids 
to obtain GFP lentiviruses that served as a transduction control. Sterile- 
filtered cell culture supernatant was used to transduce HeLa cells 
72 hours after transfection. Medium was changed 4 to 6 hours after 
transduction, followed by selection of successfully transduced cells 
(72 to 96 hours after transduction) using puromycin treatment at a con-
centration of 1.5 g/ml. Single-clone selection took place 24 to 48 hours 
after puromycin treatment by dilution of the positive cells. ISG15 
deficiency was tested by IFN- stimulation and subsequent Western 
blotting for ISG15. Control cells were generated by transduction of 
lentiviral vectors containing the Cas9 sequence without gRNAs.
Generation of adenoviral vectors
The adenoviral shuttle plasmid containing hemagglutinin (HA)–




CATGAACACGGTGCTCA-3′. The recombinant, replication-deficient 
adenovector Ad5-HA-hISG15 as well as the Ad5-control vector were 
cloned by in vitro ligation of the 5′ long arm of Xba I–digested 
E1E3 adenovirus mutant RR5. Following transfection of the con-
structs into Hek293 cells, recombinant vector preparation was per-
formed as described elsewhere (57). Concentration of the obtained 
vector preparation was determined by standard plaque assay on 
Hek293 cells.
Phagocytosis assay
BMMs were plated in 24-well plates at a density of 3 × 105 cells per 
well. After 15 min of synchronization on ice, cells were loaded with 
target particles for phagocytosis and placed again on ice to allow 
equal attachment of the particles to the cell surface. The following 
phagocytosis particles were used: pHrodo Red Escherichia coli Bio 
Particles (Life Technologies, according to the manufacturer’s in-
structions), polystyrene carboxylate-modified latex beads with 
yellow-green fluorescence (1 × 107 beads per well; Sigma-Aldrich), 
and PKH67-labeled, heat-inactivated Streptococcus pneumoniae 
(D38cps, MOI 25). After incubation at 37°C for the indicated length 
of time, cells were rinsed with ice-cold PBS to stop phagocytosis. 
Fluorescence intensity was analyzed by flow cytometry.
Determination of ROS and NO
Generation of ROS in BMMs was analyzed by 2′,7′-dichlorodihydro-
fluorescein diacetate (DCFH-DA; 10 M) staining performed in 
triplicate. After 1 hour of incubation at 37°C, cells were rinsed twice 
with PBS and fluorescence was analyzed by flow cytometry. The 
capacity of BMMs to produce NO was determined by Griess assay. 
Cell culture supernatants of 1 × 105 per 96-well BMMs were incu-
bated with Griess reagent (Molecular Probes). Nitrite concentrations 
were calculated using a reference curve.
RNA isolation and quantitative real-time  
polymerase chain reaction
RNA was isolated using the TRIzol (Ambion) method according to 
the manufacturer’s instructions. The remaining DNA was removed 
by digestion with deoxyribonuclease I (Invitrogen) at 37°C for 15 min 
followed by enzyme deactivation at 65°C for 10 min. RNA (250 to 
1000 ng) was reverse-transcribed by MLV Reverse Transcriptase 
(Promega) in combination with random hexamer primers (Roche). 
TaqMan polymerase chain reaction (PCR) was performed using 
primers and probes of TaqMan gene expression assays (Life Tech-
nologies, Germany) as well as the following combinations of primers 
and probes: human HPRT, 5′-AGTCTGGCTTATATCCAA-
CACTTCG-3′ (forward), 5′-GACTTTGCTTTCGGTCAGG-3′ 
(reverse), and 5′-TTTCACCAGCAAGCTTGCGACCTTGA-3′ 
(probe); murine HPRT, 5′-ATCATTATGCCGAGGATTTG-
GAA- 3′ (forward), 5′-TTGAGCACACAGAGGGCCA-3′ (reverse), 
and 5′FAM-TGGACAGGACTGAAAGACTTGCTCGAGATG- 
3′TAMRA (probe); and CV, 5′-CCCTGAATGCGGCTAATCC-3′ 
(forward), 5′-ATTGTCACCATAAGCAGCCA-3′ (reverse), and 
5′-FAM-TGCAGCGGAACCG-MGB3′ (probe). A StepOnePlus 
real-time PCR system was used for quantitative PCR (qPCR). 
TaqMan assays for HPRT served as endogenous controls and 
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Quantification of infectious viral particles
Plaque assays were performed on subconfluent monolayers of green 
monkey kidney cells incubated with serial 10-fold dilutions of cell 
culture supernatant or supernatant from homogenized mouse tissue. 
After incubation at 37°C for 1 hour, supernatants were removed and 
monolayers were overlaid with DMEM containing 1 mM pyruvate, 
2.5% fetal calf serum, 3.75% NaHCO3, and 0.6% agar. Two days later, 
cells were fixed with 75% methanol/25% acetic acid and stained with 
0.25% crystal violet solution to count virus plaques. In some experi-
ments, virus titers were determined by median tissue culture infec-
tious dose (TCID50) assay on green monkey kidney cells.
Immunoprecipitation
After IFN- treatment [IFN- (100 U/ml) for 24 hours], FLAG-His 
ISG15 cells (pBabe-FLAG-His ISG15) and respective controls (pBabe 
plasmid empty vector) (3) were lysed in 20 mM Hepes, 8 mM EDTA, 
2 mM EGTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 
2 mM sodium orthovanadate, 5 mM N-ethylmaleimide (NEM), 1% 
Triton X-100, and cOmplete Protease Inhibitor Cocktail (Roche). 
Total cell lysate was (2 mg) was incubated with 50 l of anti-FLAG 
M2 affinity gel (Sigma-Aldrich) for 3 hours at 4°C on a rotation 
wheel. After washing with lysis buffer, beads were incubated in 
Laemmli buffer for 10 min at room temperature and samples were 
subjected to SDS–polyacrylamide gel electrophoresis (SDS-PAGE). 
Alternatively, HeLa cells were transfected with pcDNA3.1-hUbe1L, 
pcDNA3.1-UbcM8, pTriEx2-hHERC5, and pcDNA3.1-HA-hISG15. 
FLAG-tagged IFIT1 or IFIT3 constructs were transfected a day later. 
After 24 hours, cells were lysed with Hepes buffer containing 1% 
CHAPS, 8 mM EDTA, 2 mM EGTA, 50 mM sodium fluoride, 5 mM 
sodium pyrophosphate, 2 mM sodium orthovanadate, 5 mM NEM, 
and cOmplete Protease Inhibitor Cocktail (Roche), and 2 mg of cell 
lysate was used for FLAG immunoprecipitation. Beads were washed 
with lysis buffer, high-salt buffer (200 mM Hepes, 300 mM NaCl, and 
0.1 mM EDTA), and washing buffer (200 mM Hepes and 0.1 mM 
EDTA) before elution with Laemmli buffer.
Western blot analysis
For SDS-PAGE, cells or tissues were lysed using 8 M urea buffer 
containing 1% Triton X-100, 0.1% SDS, 20 mM Hepes, 8 mM EDTA, 
2 mM EGTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 
2 mM sodium orthovanadate, 1 mM tris (2-Carboxyethyl)phosphine 
(TCEP), and cOmplete Protease Inhibitor Cocktail (Roche, Germany). 
Western blot analysis was performed according to standard protocols. 
The following primary antibodies were used: -actin (C4; Merck), FLAG 
(M2; Sigma-Aldrich), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (FL-335; Santa Cruz Biotechnology or 6C5; Invitrogen), 
ISG15 (lab stocks), human IFIT1 (polyclonal; Abcam), human IFIT3 
(polyclonal; Abcam), murine IFIT1 (polyclonal; Abcam), murine IFIT3 
(polyclonal; Antibodies Online), -tubulin (GT114; GeneTex), and 
VP1 (31A2; Mediagnost). Secondary IRD680CW- or IRDye800CW- 
labeled antibodies were detected by an Odyssey CLx infrared imaging 
system (LI-COR Biosciences). Densitometric analysis was performed 
using Image Studio (LI-COR Biosciences), and values were normalized 
to internal loading controls.
Proteomics sample preparation and LC-MS/MS analysis
Male wild-type and ISG15−/− mice were infected with 1 × 105 pfu of 
CVB3 and sacrificed at day 3 or 8 after infection. Mice that were 
treated with DMEM served as control. Liver samples (three mice 
per group, 18 samples in total) were flushed with PBS before they 
were collected and frozen in liquid nitrogen. Tissue was homogenized 
in 20 mM Hepes (pH 8.0) containing 8 M Urea before samples were 
sonicated by three pulses of 10 s at an amplitude of 20% and centri-
fuged for 15 min at 16,000 relative centrifugal force (rcf) at room 
temperature. Proteins were first reduced by addition of 5 l of dithio-
threitol to a final concentration of 5 mM and incubated for 30 min 
at 55°C and then alkylated by addition of chloroacetamide to a con-
centration of 10 mM and incubation for 15 min at room tempera-
ture. The samples were diluted to a urea concentration of 4 M, and 
1 mg of protein was digested with lysyl endopeptidase (1:250, w/w; 
Wako) for 4 hours at 37°C. After further dilution to 2 M urea, pro-
teins were digested with trypsin (1:200, w/w; Promega) overnight at 
37°C. The resulting peptide mixture was acidified by addition of 1% 
trifluoroacetic acid (TFA), and insoluble components were removed 
by centrifugation at 7000 rcf for 15 min at room temperature. Peptides 
were purified on C18 Sep-Pak columns (Waters), lyophilized, and 
stored at −80°C before LC-MS/MS analysis. Peptides were redissolved 
in loading solvent A [0.1% TFA in water/ACN (98:2, v/v)], and 
the peptide concentration was determined on a Lunatic instrument 
(Unchained Labs) to inject 3 g of peptides for LC-MS/MS analysis 
on an Ultimate 3000 RSLCnano system in-line connected to a 
Q-Exactive HF mass spectrometer (Thermo Fisher Scientific). 
Trapping was performed at 10 l/min for 4 min in loading solvent 
A on a 20-mm trapping column [100 m internal diameter (I.D.), 
5-m beads; C18 Reprosil-HD, Dr. Maisch, Germany] before the 
samples were separated on a 400-mm analytical column packed in 
the needle (75 m I.D., 1.9-m beads; C18 Reprosil-HD, Dr. Maisch). 
Before packing of the column, the fused silica capillary had been 
equipped with a laser-pulled electrospray tip using the P-2000 Laser 
Based Micropipette Puller (Sutter Instruments). Peptides were eluted 
from the analytical column by a nonlinear gradient from 2 to 56% 
solvent B [0.1% FA in water/acetonitrile (2:8, v/v)] over 145 min at 
a constant flow rate of 250 nl/min, followed by a 5-min increase to 
97% solvent B and an additional 10 min wash in solvent B. The col-
umn was then reequilibrated with 98% solvent A (0.1% FA in water) 
for 20 min. The column temperature was kept constant at 50°C in a 
column oven (Sonation COControl). The mass spectrometer was op-
erated in data-dependent mode, automatically switching between MS 
and MS/MS acquisition for the 16 most abundant ion peaks per MS 
spectrum. Full-scan MS spectra [375 to 1500 mass/charge ratio (m/z)] 
were acquired at a resolution of 60,000 in the Orbitrap analyzer after 
accumulation to a target value of 3 × 106. The 16 most intense ions 
above a threshold value of 1.3 × 104 were isolated for fragmentation at 
a normalized collision energy of 28% after filling the trap at a target value 
of 1 × 105 for maximum 80 ms. MS/MS spectra (200 to 2000 m/z) 
were acquired at a resolution of 15,000 in an Orbitrap analyzer.
Data processing and GO term enrichment analysis
Data analysis was performed with MaxQuant (version 1.6.3.4) us-
ing the Andromeda search engine with default search settings in-
cluding a false discovery rate (FDR) set at 1% on both the peptide 
and protein level. The recorded spectral data files were searched 
together against all mouse proteins in the UniProt/Swiss-Prot 
database [database release version of January 2019 containing 
17,006 murine protein sequences (taxonomy ID 9606), downloaded 
from www.uniprot.org] supplemented with all precursor and mature 
proteins encoded in the CVB3 genome in the UniProt/Swiss-Prot 
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CVB3 protein sequences (taxonomy ID 103903), downloaded from 
www.uniprot.org]. The mass tolerance for precursor and fragment 
was set to 4.5 and 20 parts per million, respectively, during main 
search. Enzyme specificity was set as C-terminal to arginine and lysine 
(trypsin), also allowing cleavage at arginine/lysine-proline bonds 
with a maximum of two missed cleavages. Carbamidomethylation 
of cysteine residues was set as a fixed modification, and variable 
modifications were set to oxidation of methionine (to sulfoxides) 
and acetylation of protein N termini. Matching between runs was 
enabled with an alignment time window of 20 min and a matching 
time window of 1 min. Only proteins with at least one unique peptide 
were retained, leading to the identification of 3982 mouse proteins 
in all 18 samples. Further data analysis was performed with the Perseus 
software (version 1.6.1.1) after loading the proteinGroups table from 
MaxQuant. Hits identified in the reverse database and as potential 
contaminants were removed, and protein label-free quantification 
(LFQ) intensities for each sample were log2-transformed. Replicate 
samples were grouped, proteins with less than three valid values in 
at least one group were removed, and missing values were imputed 
from a normal distribution around the detection limit to compile a 
list of 2655 quantified proteins (table S1A). To reveal significantly 
regulated proteins, two t tests (FDR = 0.05, S0 = 1) were performed 
to compare protein intensities between days 0 and 3 after infection 
in wild-type mice (table S1B). To identify proteins that were signifi-
cantly regulated across all samples, groups were defined based on 
genotypes (wild-type versus ISG15−/−) and time after infection (day 0 
versus day 3 versus day 8), and a two-way analysis of variance 
(ANOVA) test was performed to compare the protein intensities in 
the infection group with the genotype group. For each protein, this 
test calculated a P value for infection, a P value for genotype, and a 
P value for the interaction between both groups. This test revealed 
1094 significantly regulated proteins with P ≤ 0.05 in at least one of 
the three conditions. The intensities of these proteins are shown in 
the heatmap in Fig. 4A after z scoring and nonsupervised hierarchical 
clustering. To further dissect the regulation between wild-type and 
ISG15−/− mice, the ANOVA-regulated proteins were clustered in 
two separate heatmaps and are reported in table S1C. The first heat-
map displays the protein intensities of wild-type mice at days 0, 3, 
and 8 after infection (Fig. 4A, left), while the second heatmap shows 
the protein intensities of ISG15−/− mice at days 0, 3, and 8 after in-
fection (Fig. 4A, right). In both heatmaps, six clusters with the same 
regulation pattern were distinguished. To visualize the overlap be-
tween each cluster in both heatmaps for wild-type versus ISG15−/− 
mice, Venn diagrams were created using MATLAB (R2018a) (Fig. 4B). 
Last, GO enrichment analysis was performed on four protein lists 
derived from both heatmaps. The first list contains the proteins 
up-regulated at day 3 after infection, and the second list contains the 
proteins up-regulated at day 8 after infection. Proteins up-regulated 
at both days were included into both lists. Likewise, two lists per 
genotype were generated for proteins that were down-regulated on 
days 3 and 8 after infection. GO term enrichment analysis was per-
formed using the GO consortium bioinformatics resources (58), and 
proteins associated with selected GO terms were listed in Figs. 4C 
and 6C using MATLAB (R2018a).
Modeling of central liver metabolism
We used HEPATOKIN1, a model of central liver metabolism (43), 
to assess the metabolic alterations during viral infection. We con-
structed strain- and condition-dependent metabolic models by scaling 
the maximal activity for each enzyme and transporter in the model 
according to proteomic data. Therefore, we used the LFQ intensities 
obtained from MaxQuant analysis according to  V max 
 E *  =  V max 
E ⋅   E *  _  E ref , 
where  V max 
 E *  is the maximal enzyme activity for E in the considered 
condition, E* is the LFQ intensity in the considered condition, Eref 
is the LFQ intensity in the reference state, and  V max 
E is the maximal 
enzyme activity in the reference state. The reference values used were 
taken from the generic model for a healthy liver (43). The strain- and 
infection-dependent metabolic response of the liver was calculated 
according to varying plasma metabolite profiles and hormones 
including glucose, lactate, pyruvate, glycerol, FFAs, acetoacetate, 
-hydroxybutyrate, oxygen, ammonia, glutamine, glutamate, serine, 
alanine, insulin, and glucagon. We simulated either (i) the metabolic 
output of the liver over a standardized diurnal cycle defined in (43) 
(Fig. 5D and fig. S6B) or (ii) the glucose exchange flux of the liver 
for the physiological range of plasma glucose concentrations between 
3 mM (54 mg/dl) and 10 mM (180 mg/dl) (Fig. 5E and fig. S6C). For 
(i), we evaluated the metabolic state of the liver at any time point of 
the 24-hour cycle in response to the time-dependent variations of the 
metabolite and hormone concentrations in the blood plasma profile, 
followed by averaging of glucose and lactate exchange fluxes as well as 
the FA uptake rates over 24 hours (fig. S6B). For (ii), we systematical-
ly varied the plasma glucose concentration in the physiological range 
while, at the same time, varying the FA plasma concentrations and the 
plasma concentrations of insulin and glucagon using both the glucose- 
FFA and hormone-glucose transfer function defined in (43). These 
calculations are plausible because the pancreas, in response to altered 
concentrations of plasma glucose, secretes insulin and glucagon. Both 
hormones also control the plasma concentration of FAs, mainly by 
altered lipolysis of triglycerides in adipose tissue. For details, see (43).
Measurement of metabolites
The levels of glucose and lactate in cell culture supernatants of 
CV-infected HeLa cells were determined using an ABL800 FLEX 
blood gas analyzer. Cell culture supernatants were collected 32 hours 
after infection, and cell debris was removed by centrifugation for 
5 min at 500 rcf before duplicate samples were applied to the blood 
gas analyzer. Baseline concentrations in medium were subtracted, 
and values were normalized to cell number per well. To monitor 
metabolite concentrations in vivo, wild-type and ISG15−/− mice were 
sacrificed at days 0, 3, and 8 after infection. Blood samples were taken, 
and the glucose concentration was determined using an Accu-Check 
glucometer (Roche). Serum FFA concentrations were measured us-
ing the colorimetric Free Fatty Acid Kit (Abcam) according to the 
manufacturer’s instructions. The concentration of triglycerides in 
sera of infected mice was analyzed by the Institute for Veterinary 
Diagnostics (Berlin). To determine the hepatic glucose content, tissue 
samples were homogenized in PBS using a FastPrep 120 cell dis-
rupter (Thermo Savant), followed by three freeze-thaw cycles. Cell 
debris was removed by centrifugation for 10 min at 13,000 rcf. 
Supernatants were collected and applied to the ABL800 FLEX blood 
gas analyzer. Paraffin-embedded tissue sections were used to visualize 
hepatic glycogen. Samples were first oxidized in 0.5% periodic acid 
solution, followed by incubation with Schiff’s reagent for 15 min as 
well as counterstaining with Mayer’s hematoxylin.
Seahorse metabolic assessment
Analysis of mitochondrial oxidative metabolism was conducted using 









Kespohl et al., Sci. Adv. 2020; 6 : eaay1109     11 March 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
17 of 19
function was assessed by evaluating basal oxygen consumption and 
extracellular acidification rate in DMEM-based assay medium with 
2 mM glutamine and 10 mM glucose from liver samples (1-mm 
punches) (59). All data were normalized to total protein content per 
well as determined by the Micro BCA Protein Assay Kit (Thermo 
Fisher Scientific). Outliers were excluded after analysis using Grubbs’ 
test in GraphPad Prism 8.
Statistics/data availability
Statistical analysis of the data was performed in GraphPad Prism 
v7.00 for Windows (GraphPad Software, La Jolla, USA). All data are 
plotted as individual points. If not indicated otherwise, data sum-
maries are given as means ± SEM. Unpaired t tests were used for 
two-group comparisons. If samples had unequal variances (deter-
mined by an F test), an unpaired t test with the Welch correction was 
used. If values were normalized to an internal control, one-sample 
t tests were applied. For multiple group comparison, unequal vari-
ance versions of ANOVA (one-way or two-way ANOVA) were per-
formed followed by multiple comparison test. The significance 
threshold for all tests was set at the 0.05 level. The MS proteomics 
data have been deposited to the ProteomeXchange Consortium via the 
PRIDE (60) partner repository with the dataset identifier PXD013259.
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